JAK Inhibitors for Alopecia: What Monitoring Do Patients Actually Need?

Alopecia areata, a chronic immune-mediated disease, presents a significant challenge for both patients and clinicians due to its unpredictable nature and the psychological burden it imposes. Historically, treatment options were largely limited to corticosteroids, topical immunotherapy, or other broad immunosuppressants, which often yielded inconsistent results and carried substantial systemic risks. The understanding of AA's immunopathogenesis has advanced considerably, pinpointing the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway as a key driver. This pathway mediates the signaling of cytokines like interferon-γ and interleukin-15, which are central to the autoimmune attack on hair follicles.¹

The development of targeted JAK inhibitors has provided a new class of agents that directly interfere with this pathway. Baricitinib, ritlecitinib, and deuruxolitinib have all received regulatory approval for severe AA, based on phase 3 trials that demonstrated clinically meaningful scalp hair regrowth, which was essential for their approval. These responses often deepen with continuous therapy, and long-term extension studies, alongside real-world data, support their effectiveness and manageable safety profiles in carefully selected patient populations.^1-3

Understanding the JAK-STAT Pathway and Its Implications

The JAK-STAT pathway is a critical intracellular signaling cascade involved in numerous cellular processes, including immune function, haematopoiesis, and cell growth. JAK inhibitors work by blocking the activity of specific JAK enzymes (JAK1, JAK2, JAK3, TYK2), thereby disrupting the signaling of various cytokines that rely on these enzymes. In AA, the overactivity of this pathway drives the autoimmune destruction of hair follicles. By inhibiting JAKs, these drugs aim to dampen the inflammatory response and allow hair regrowth.¹

But the broad involvement of the JAK-STAT pathway means that inhibiting it can have systemic effects beyond hair follicles. This is why careful patient selection and ongoing monitoring are not merely good practice, but essential for patient safety. The safety profile of JAK inhibitors, particularly in conditions like rheumatoid arthritis, has been a subject of intense scrutiny, as seen in the ORAL Surveillance JAK inhibitor controversy. While AA is a different disease, some of the same safety considerations apply, demanding a proactive approach to risk mitigation.²

Pre-treatment Screening: Laying the Groundwork for Safety

Before initiating JAK inhibitor therapy for AA, a comprehensive pre-treatment assessment is mandatory to identify potential contraindications and baseline risks. This includes a thorough medical history, focusing on cardiovascular disease, malignancy, and a history of serious infections, particularly tuberculosis and herpes zoster. Patients with active serious infections should not start JAK inhibitor therapy. Screening for latent tuberculosis is essential for preventing reactivation, typically involving an interferon-gamma release assay (IGRA) or a tuberculin skin test. If latent TB is detected, treatment should be completed before starting the JAK inhibitor.²

Baseline laboratory investigations are also essential. A complete blood count (CBC) with differential is required to assess for anaemia, neutropenia, and lymphopenia, as these can be exacerbated by JAK inhibitors. Renal and hepatic function tests are necessary to guide appropriate dosing, as many JAK inhibitors are metabolised by the liver or excreted by the kidneys. Lipid panel assessment, including total cholesterol, LDL-C, HDL-C, and triglycerides, is also part of the baseline workup, given the known association of JAK inhibitors with dyslipidaemia.²

Vaccination status should be reviewed. Live attenuated vaccines are contraindicated during JAK inhibitor therapy, and patients should complete all recommended vaccinations, including zoster vaccine, prior to initiation. For patients considering treatment, a discussion of these pre-treatment requirements, including the need for multiple blood tests and potential delays for infection management, is vital for managing expectations.²

Ongoing Monitoring During Therapy: A Continuous Vigilance

Once JAK inhibitor therapy begins, regular monitoring is important to detect and manage potential adverse events. The frequency of monitoring typically decreases after the initial phase, but it never ceases. Haematological parameters, specifically CBC with differential, require close attention. Neutropenia and lymphopenia are common adverse events, and severe cases may necessitate dose reduction or temporary interruption of therapy. Monitoring schedules often involve checks at 4 weeks, 8 weeks, 12 weeks, and then every 3-6 months, depending on the specific agent and patient risk factors.²

Lipid levels also require ongoing surveillance. JAK inhibitors can elevate cholesterol levels, particularly LDL-C. A repeat lipid panel is typically recommended at 12 weeks after initiation, and then periodically thereafter. If significant dyslipidaemia develops, clinicians should consider lifestyle modifications or initiate lipid-lowering therapy, such as statins. The Oxford Handbook of General Practice provides a concise overview of managing common lipid disorders in primary care.

Patients should be counselled on the signs and symptoms of infection, including fever, persistent cough, and skin lesions, and instructed to report these promptly. Regular skin examinations are advisable, particularly for patients with a history of skin cancer, due to a potential increased risk of non-melanoma skin cancers with long-term JAK inhibitor use. Cardiovascular risk factors should be continually assessed and managed, as some JAK inhibitors have been associated with an increased risk of major adverse cardiovascular events (MACE) in specific populations, though this risk profile may differ across indications and patient demographics.²

Specific Safety Signals and Real-World Data

The real-world retrospective cohort study by Facheris, Gargiulo, and Ibba, published in Dermatology and Therapy (Heidelberg), provided valuable insights into JAK inhibitor safety in both atopic dermatitis and alopecia areata over 4.5 years.² This study, while not a randomised controlled trial, offered a practical perspective on the adverse event profile in a broader patient population than typically seen in trials that led to approval. The authors found that the safety profiles were manageable in appropriately selected patients, reinforcing the importance of adherence to monitoring guidelines.²

The most frequently reported adverse events included infections, particularly upper respiratory tract infections and herpes zoster reactivation. This aligns with the known mechanism of action of JAK inhibitors, which modulate immune responses. Haematological abnormalities, such as lymphopenia and neutropenia, also occurred, necessitating dose adjustments in some cases. The study did not identify any new or unexpected safety signals, but it highlighted the need for continuous vigilance, especially regarding opportunistic infections and haematological changes.²

But the real-world setting often includes patients with more comorbidities than those enrolled in highly controlled clinical trials. This means that while the overall safety profile may be manageable, individual patient risk stratification remains paramount. The study's retrospective nature is an obvious caveat; it cannot establish causality with the same certainty as a prospective, randomised trial. However, it offers a pragmatic view of how these drugs perform in routine clinical practice, which is invaluable for clinicians making prescribing decisions.²

Duration of Treatment and Response Assessment

The question of how long to treat to achieve desired outcomes with JAK inhibitors, particularly baricitinib 4 mg, was addressed by King, Senna, and Ohyama in Dermatology and Therapy (Heidelberg).³ Their evidence-based approach highlighted that responses often deepen over time under continuous therapy. This suggests that patients may require sustained treatment to achieve optimal hair regrowth, and premature discontinuation could lead to suboptimal outcomes or relapse.³

Clinicians should assess treatment response periodically, typically using tools like the Severity of Alopecia Tool (SALT) score. A clinically meaningful response is often defined as achieving a SALT score of 20 or less (meaning 20% or less scalp hair loss). Patients who show an initial response but have not yet reached their desired outcome may benefit from continued therapy, as further improvement is possible. This long-term commitment to therapy also reinforces the need for consistent monitoring, as the cumulative risk of adverse events may increase over time.³

The decision to continue or discontinue therapy should be a shared one, considering the patient's response, tolerability, and overall risk-benefit profile. For patients who achieve near-complete or complete regrowth, the question of maintenance therapy versus gradual tapering arises, though current evidence on optimal discontinuation strategies is still evolving. The absence of head-to-head trials comparing the approved JAK inhibitors means that indirect comparative analyses should be interpreted cautiously when considering differences in short-term efficacy.¹

Where the Evidence Falls Short

Despite the significant advances, several gaps remain in the evidence base for JAK inhibitors in AA. A substantial proportion of patients do not achieve near-complete or complete regrowth, indicating a need for alternative or combination therapies. All currently approved systemic medicines for AA belong to the same drug class, limiting options for patients who do not respond or cannot tolerate JAK inhibitors.¹

There are currently no JAK inhibitors approved for pre-adolescents, leaving a significant unmet need in paediatric populations. While pediatric development programs and real-world observational studies are broadening the evidence base across age groups, specific guidelines for younger patients are still developing. The long-term safety data, particularly regarding malignancy and major adverse cardiovascular events in younger patients or those with fewer comorbidities, will require continued surveillance.^1,2

The lack of direct comparative trials between baricitinib, ritlecitinib, and deuruxolitinib means that clinicians must rely on indirect comparisons, which carry inherent limitations. While these analyses may suggest differences in short-term efficacy, definitive conclusions about superiority or differential safety profiles across the class are not yet possible. The field awaits further research into predictive biomarkers that could identify patients most likely to respond to JAK inhibitors, thereby optimising treatment selection and minimising unnecessary exposure to potential risks.¹